Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AMG 193 (Primary) ; Docetaxel (Primary)
  • Indications Adenocarcinoma; Brain cancer; Cholangiocarcinoma; Gastric cancer; Glioma; Head and neck cancer; Lymphoma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Amgen

    • Most Recent Events

    • 22 Aug 2024 Planned End Date changed from 12 Mar 2029 to 28 Dec 2027.
    • 22 Aug 2024 Planned primary completion date changed from 11 Nov 2027 to 31 Mar 2026.
    • 01 Jul 2024 Protocol amended with addition of patients to 649 having MTAP-null esophageal/gastric cancer and glioma in Parts 1m of drug regime.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top